LatAm MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe 2025. Latin America is at a pivotal moment in the evolution of its regulatory systems. Factors such as the adoption…

Europe Writing in the June 2025 edition of DIA’s Global Forum Magazine, Finn McCartney, Maria Dutarte, Petra Adámková, and Paola Kruger from the European Patients’ Academy on Therapeutic Innovation (EUPATI) weigh in on how the patient voice is being incorporated into Joint Clinical Assessments (JCA) under the new EU Health Technology…

Canada Dr David Reddy, Director General, IFPMA, and Dr Bettina Hamelin, President, IMC, jointly advocate for health innovation at the 2025 G7 Summit in Kananaskis (15-17 June). They call G7 leaders to place health and life-sciences innovation at the heart of the G7 agenda, emphasizing three areas of focus where the…

Europe Lora Fleifel, Director of Global Value Access & Pricing Operations Europe for Oncology at Merck, dissects the promise and pitfalls of the new EU Joint Clinical Assessment (JCA). The JCA aims to harmonise clinical evaluations to help reduce the significant disparities in patient access to innovative treatments that still exist…

Global Writing in ISPOR’s Value and Outcomes Spotlight magazine, Beth Fand Incollingo looks at why health economics and outcomes research may hold the key to solving some of healthcare’s most entrenched access and affordability issues.   Healthcare can only be widely effective if most patients can access and afford it. Yet,…

Global We are living in uncertain times. The US government’s rapid-fire retreat from development aid and multilateral participation has shaken up the global system but – as Brendan Shaw argues, reflecting on the 2025 World Health Assembly – this has created a major opportunity to reshape the international order for the…

Americas Diego Salas from the Latin American Federation of the Pharmaceutical Industry (FIFARMA) and Carlos Felipe Escobar Roa from the Instituto de Prospectiva e Innovacion en Salud (INNOS), writing in the May 2025 edition of DIA’s Global Forum magazine, discuss the findings of a pioneering report launched at the end of…

Australia Australia will shortly have its latest national election, and we are again seeing pharmaceuticals being front and centre in the campaign.   The starter’s gun has been fired for the 2025 Australian federal election, which will be held on Saturday, 3 May, just 5 days after Canada’s forthcoming national election.…

Global Writing in the April 2025 edition of DIA’s Global Forum magazine, Christopher Morrison and Richard Xie of RA Capital Management L.P., introduce the recently published cost-effectiveness analyses methodology which incorporates key value elements and drivers that are omitted or incompletely captured in traditional clinical outcome assessments.   Accelerating scientific discoveries…

APAC This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers China’s USD 36.2bn in outbound licensing agreements, Henlius & EssexBio meeting Phase III endpoints, Organon acquiring US rights of tocilizumab biosimilar from Biogen, GE Healthcare’s acquisition of Japan’s Nihon Medi-Physics, Wuxi Biologics’ disposal of vaccine facility to…

APAC This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers the AACR 2025 ADC pipeline list from China, Puhe out-licensing global rights of a PRMT5 inhibitor to Bayer, AbbVie accusing Genmab of ADC trade secret theft on ADC technology used by ProfoundBio, and Singapore’s A*STAR investing in…

China 2024 was another groundbreaking year for Chinese medicine approvals. Writing in the March 2025 edition of DIA’s Global Forum magazine, Juan Valencia S. and Angel Shao of PharmCube explain how and why.   Driven by drugmakers’ growing interest in accessing the world’s second-largest pharmaceutical market, China has recently seen a…